Zacks Investment Research lowered shares of Zafgen (NASDAQ:ZFGN) from a buy rating to a hold rating in a research report released on Saturday, January 13th.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine cut shares of Zafgen from a sell rating to a strong sell rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. Zafgen has a consensus rating of Hold and an average price target of $6.63.
Zafgen (ZFGN) traded up $0.52 during mid-day trading on Friday, reaching $6.05. 156,284 shares of the company’s stock were exchanged, compared to its average volume of 156,485. Zafgen has a 1 year low of $3.21 and a 1 year high of $6.18. The company has a market capitalization of $152.02, a PE ratio of -3.34 and a beta of -1.25.
Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.12. analysts expect that Zafgen will post -2.02 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in shares of Zafgen during the 2nd quarter valued at $259,000. Vanguard Group Inc. lifted its position in Zafgen by 15.7% in the 2nd quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock worth $3,102,000 after buying an additional 119,902 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Zafgen by 31.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 140,848 shares during the last quarter. OxFORD Asset Management LLP bought a new stake in Zafgen in the 2nd quarter worth approximately $364,000. Finally, Goldman Sachs Group Inc. lifted its position in Zafgen by 1,701.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock worth $692,000 after buying an additional 186,336 shares during the last quarter. 48.60% of the stock is owned by institutional investors.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.